Please use this identifier to cite or link to this item:
Title: Effect of cost sharing on adherence to evidence based medications in patients with acute coronary syndrome
Authors: González López-Valcárcel, Beatriz 
Librero, Julian
García Sempere, A.
Peña, Luz Marina
Bauer, S.
Puig Junoy,Jaume 
Oliva Moreno, J.
Peiro, Salvador
Sanfelix-Gimeno, Gabriel
UNESCO Clasification: 531207 Sanidad
Keywords: Coste farmacéutico
Issue Date: 2017
Journal: Heart 
Abstract: Objectives Cost-sharing scheme for pharmaceuticals in Spain changed in July 2012. Our aim was to assess the impact of this change on adherence to essential medication in patients with acute coronary syndrome (ACS) in the region of Valencia. Methods Population-based retrospective cohort of 10 563 patients discharged alive after an ACS in 2009–2011. We examined a control group (low-income working population) that did not change their coinsurance status, and two intervention groups: pensioners who moved from full coverage to 10% coinsurance and middle-income to high-income working population, for whom coinsurance rose from 40% to 50% or 60%. Weekly adherence rates measured from the date of the first prescription. Days with available medication were estimated by linking prescribed and filled medications during the follow-up period. Results Cost-sharing change made no significant differences in adherence between intervention and control groups for essential medications with low price and low patient maximum coinsurance, such as antiplatelet and beta-blockers. For costlier ACE inhibitor or an angiotensin II receptor blocker (ACEI/ARB) and statins, it had an immediate effect in the proportion of adherence in the pensioner group as compared with the control group (6.8% and 8.3% decrease of adherence, respectively, p<0.01 for both). Adherence to statins decreased for the middle-income to high-income group as compared with the control group (7.8% increase of non-adherence, p<0.01). These effects seemed temporary. Conclusions Coinsurance changes may lead to decreased adherence to proven, effective therapies, especially for higher priced agents with higher patient cost share. Consideration should be given to fully exempt high-risk patients from drug cost sharing.
ISSN: 1355-6037
DOI: 10.1136/heartjnl-2016-310610
Source: Heart [ISSN1355-6037], v. 103 (14)
Rights: by-nc-nd
Appears in Collections:Artículos

Files in This Item:
File Description SizeFormat 
0732042_00000_0000.pdf460,2 kBAdobe PDFView/Open
Show full item record


checked on Nov 16, 2019


checked on Nov 16, 2019

Page view(s) 50

checked on Nov 16, 2019

Download(s) 50

checked on Nov 16, 2019

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.